Kite Pharma Is Up Because Of This Slideshow
Kite Pharma Inc (NASDAQ: KITE) is trading higher on Wednesday after the company presented at the 2015 Jefferies Now at the Immuno-Oncology Summit in Boston.
The company has been a solid performer in 2015, and is up 120 percent in the past year.
In the presentation, Kite Pharma discussed everything from an expanding pipeline to its plan to "transform cancer therapy." In particular, the company highlights its TCRs, which are aimed at what it calls "a broad spectrum of therapeutic tumor targets.
"Kite Pharma is uniquely positioned to address an unmet need and target a large hidden opportunity," it adds.
Check out the full slides below.
Latest Ratings for KITE
|Mar 2017||Standpoint Research||Downgrades||Buy||Hold|
|Mar 2017||Stifel Nicolaus||Downgrades||Buy||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.